Reading view
DrugRAG: Enhancing Pharmacy LLM Performance Through A Novel Retrieval-Augmented Generation Pipeline
MedChat: A Multi-Agent Framework for Multimodal Diagnosis with Large Language Models
Multimodal Foundation Models for Early Disease Detection
A novel statistical feature selection framework for biomarker discovery and cancer classification via multiomics integration
BMC Med Res Methodol. 2025 Dec 17. doi: 10.1186/s12874-025-02713-z. Online ahead of print.
ABSTRACT
BACKGROUND: Early cancer diagnosis is essential for improving prognosis and guiding treatment. However, the high dimensionality and complexity of omics data present major challenges. Computational approaches that extract stable biomarkers and enable reliable classification across cancer types and stages are needed.
METHODS: A novel feature selection method, sDCFE (synergistic Discriminative Cluster-based Feature Extraction), was developed by extending Fisher-like variance analysis with a median absolute deviation (MAD) regularization term and a cluster separation component to enhance robustness and interpretability. Features selected by sDCFE were compared with those obtained from XGBoost, and the intersected set of 82 genes was evaluated through functional enrichment (KEGG, Reactome, GO BP), survival analysis (Kaplan-Meier, Cox regression), and biomarker novelty assessment against six external resources. Hybrid classification models integrating XGBoost, sDCFE, and deep learning were applied to pancancer classification, and the framework was further extended to lung squamous cell carcinoma (LUSC) staging using RNA-seq and methylation data.
RESULTS: The overlap between sDCFE and XGBoost yielded 82 candidate biomarkers enriched in cancer-related pathways, including cell cycle regulation, immune signalling, and DNA repair. Novelty assessment stratified these genes into established, emerging, and novel categories. Six genes-HFE2, LOC339674, SERINC2, SFTA3, SOX2OT, and ACPP-emerged as the most promising candidates, supported by enrichment and survival associations across multiple cancers. The hybrid model achieved near-perfect pancancer classification on TCGA (accuracy = 99.3%, MCC = 0.992, AUC = 1.0) and demonstrated strong generalizability on PCAWG (accuracy = 94%, MCC = 0.929, AUC = 0.997). In the LUSC staging task, multiomics integration improved classification performance: the CNN-based model reached 84% accuracy, while logistic regression applied to sDCFE-ranked features achieved 88.5% accuracy with superior calibration, highlighting the robustness of the selected features.
CONCLUSION: sDCFE provides a principled extension of Fisher-like methods, enabling stable and interpretable biomarker selection. When combined with XGBoost and deep learning, the framework achieves highly accurate and biologically grounded cancer classification across both cancer types and stages. The identification of novel and prognostic biomarkers, including HFE2, LOC339674, SERINC2, SFTA3, SOX2OT, and ACPP, underscores its translational potential. These results position the framework as a promising precision oncology tool to support early diagnosis, risk stratification, and treatment decision-making.
PMID:41408184 | DOI:10.1186/s12874-025-02713-z
Enhancing Transparency and Traceability in Healthcare AI: The AI Product Passport
Graph AI generates neurological hypotheses validated in molecular, organoid, and clinical systems
Criminal Liability in AI-Enabled Autonomous Vehicles: A Comparative Study
A Multicenter Benchmark of Multiple Instance Learning Models for Lymphoma Subtyping from HE-stained Whole Slide Images
COMMA: A Communicative Multimodal Multi-Agent Benchmark
A Knowledge Graph-based Retrieval-Augmented Generation Framework for Algorithm Selection in the Facility Layout Problem
Beyond Task Completion: An Assessment Framework for Evaluating Agentic AI Systems
Immunological sin: how a person’s earliest flu infections dictate life-long immunity
Nature, Published online: 17 December 2025; doi:10.1038/d41586-025-03606-3
Researchers are striving to understand the impact a phenomenon known as original antigenic sin has on immunity to the virus.Do we need prequalification of AI as a medical device to drive equitable adoption
npj Digital Medicine, Published online: 17 December 2025; doi:10.1038/s41746-025-02151-7
Do we need prequalification of AI as a medical device to drive equitable adoptionArtificial Intelligence Platform Architecture for Hospital Systems: Systematic Review
Single-cell and spatial transcriptomic characterization of pulmonary pleomorphic carcinoma
Commun Biol. 2025 Dec 16;8(1):1773. doi: 10.1038/s42003-025-09162-w.
ABSTRACT
Pulmonary pleomorphic carcinoma (PPC) is a rare subtype of lung cancer that comprises both epithelial and sarcomatoid components. The molecular basis of PPC, including the cellular dynamics of its components, remains largely unknown. To elucidate potential therapeutic targets for PPC, we perform a multi-omics analysis incorporating digital spatial profiling and single-cell RNA sequencing (scRNA-seq). PPC exhibits diverse driver gene alterations, including MET exon 14 skipping mutation (METex14) and ALK fusion. In spatial transcriptomics, MET gene and protein are overexpressed exclusively within the epithelial component and not in the sarcomatoid component, even in patients harboring METex14. Epithelial-mesenchymal transition (EMT)-related transcriptional changes, along with extracellular matrix (ECM) remodeling between the epithelial and sarcomatoid components, are observed. scRNA-seq identifies cell populations within the epithelial component that contribute to the malignant transformation and differentiation of the sarcomatoid component. They are characterized by an intermediate EMT state with ECM remodeling signature, suggesting their potential as novel therapeutic targets for PPC.
PMID:41402584 | PMC:PMC12708732 | DOI:10.1038/s42003-025-09162-w
STAT+: Key digital health and device leaders depart FDA
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
A tumultuous year at the Food and Drug Administration will be capped off at the agency’s devices center with the departure of two key leaders, just as regulators are sorting through challenges related to artificial intelligence and launching new initiatives on software as a medical device regulation.
- Sources tell us Jessica Paulsen, a 15-year veteran of FDA and acting deputy director of its Digital Health Center of Excellence is leaving the agency. She’s been leading the center since last summer when the last acting head, SonjaFulmer, left FDA for Mayo Clinic. Fulmer took over for Troy Tazbaz who left in January to return to Oracle. The center’s work includes communicating with industry and developing guidances relevant to digital health. (FDA did not respond to a request for comment.)
- Neuralink, Elon Musk’s frothy brain-computer interface company, poached David McMullen, director of FDA’s office of neurological and physical medicine devices, which is in charge of regulating Neuralink. McMullen spent three years atop the office and previously worked at the National Institute for Mental Health.
- Both Paulsen and McMullen were at the forefront of important conversations about the future of regulation. I grabbed the screenshot above of the two leaders from a video of last month’s Digital Health Advisory Committee meeting on generative AI-enabled mental health devices. Separately, McMullen’s office will have oversight of behavioral health devices under the FDA’s new TEMPO pilot.
- New to me: As part of the funding package that reopened the government last month, lawmakers passed full-year 2026 funding for FDA. Buried within the Senate report accompanying the legislation, lawmakers direct FDA to, within 90 days, (February) report on its authorities to regulate AI medical devices, and within 180 days, (May) report on “the status of the FDA’s efforts regarding engagement on AI in drug development.”
- The Government Accountability Office last week released a report on medical device recalls which found, among other things, that “insufficient staff limit FDA’s ability to conduct oversight activities.” In other words, the FDA already does not have enough staff to oversee medical devices and is losing key leadership at a time when new technology and initiatives may require additional horsepower.
The future of the mammogram
Applying AI to mammograms to help radiologists spot signs of breast cancer is increasingly common but researchers and AI companies want to apply new analyses to the routine screening tests to trigger more proactive care to prevent future cancers, heart attacks, and strokes. In one important breakthrough, the startup Clairity received FDA authorization for AI that offer a prediction of somone’s five-year breast cancer risk based on a mammogram alone.
Continue to STAT+ to read the full story…


© Adobe